Adams 1994.

Methods	Design: parallel group randomized trial Duration of study: March to May 1990 Duration of follow‐up: 63 days
Participants	Country: Kenya Setting: school Number included in study: 56 Age: 5–10 years Sex: 31 girls, 25 boys Inclusion criteria: children in nursery and standard 1 classes of Mvindeni Primary School in Kwale District Coast Province Kenya, who had more than 500 epg of T trichiura or > 1000 epg of A lumbricoides or hookworm, prepubertal and > 5 years old Lost at follow‐up: 1 (1.8%) Number positive for A lumbricoides: 16 Number included in review: 16 Exclusion criteria: children with severe anaemia
Interventions	Treatment strategy: screening and treat all included participants Group 1: albendazole 400 mg single dose 3 consecutive days (n = 9) Group 2: placebo (n = 7)
Outcomes	Outcomes included:Ascaris prevalence pre‐ and post‐treatment, pre‐ and post‐treatment AM and GM epg, ERR. Outcomes not included in review: efficacy of anthelmintic treatment for T trichiura and hookworm and anthropometric measurements, activity and appetite, haemoglobin concentration
Notes	Diagnostic technique: Modified Kato‐Katz Funding support: Thrasher Research Fund, SmithKline Beecham, Ltd. and NIH Nutrition Training Grant 2‐T32‐DK07158
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "subjects were grouped according to sex and paired according to hookworm intensity; one of each pair was allocated at random to the albendazole‐treated group or the placebo group."
Allocation concealment (selection bias)	Unclear risk	Details not reported.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "three 400 mg doses of either albendazole (SmithKline Beecham, Brentford, Middlesex, U.K.) or an identical‐appearing placebo were administered to each child on three consecutive school days (MIMS Africa 1989)."
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Details not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	1 (1.8%) participant lost to follow‐up and data not considered in analysis.
Selective reporting (reporting bias)	High risk	Adverse events not reported.
Other bias	Low risk	No obvious source of other bias.